

- The goal is to find if  $S_0(t)$  is 'different' from  $S_1(t)$  using a suitable metric (e.g.  $D(a,b) = \int_a^b |S_0(t) - S_1(t)| dt$  for some  $[a,b] \subseteq (0,\infty)$ )
- Suppose the study is censored at a time C and we observe only censored time  $Y=\min(T,C)$  and its censoring indicator  $\Delta=\mathbb{I}(T\leq C)$
- Thus, for each subject i = 1, 2, ..., n, we observe the triplet  $(Y_i, \Delta_i, z_i)$  where  $Y_i = \min(T_i, C_i)$  and  $\Delta_i = \mathbb{I}(T_i \leq C_i)$
- Assume  $(T_i, C_i, Z_i) \stackrel{iid}{\sim} (T, C, Z)$  for  $i = 1, \dots, n$  where  $T \perp C | Z$

ASA BioPharm Section Workshop



- How do we model the conditional survival function S(t|z)?
- Three popular models are based on conditional hazard function  $h(t|z) = \frac{\partial}{\partial t}(-\log S(t|z))$ . Let  $h_j(t) = h(t|z=j)$  for j = 0, 1

(i) Proportional hazards (PH):  $h_1(t) = \eta h_0(t)$  for some  $\eta > 0$ Equivalently,  $S_1(t) = S_0(t)^\eta$ 

- (ii) Accelerated Failure Time (AFT):  $h_1(t) = \eta h_0(\eta t)$  for some  $\eta > 0$ Equivalently,  $S_1(t) = S_0(t\eta)$
- (iii) Proprtional Odds (PO):  $\frac{1-S_1(t)}{S_1(t)} = \eta \frac{1-S_0(t)}{S_0(t)}$  for some  $\eta > 0$
- There are only two possibilities for any of these three models:
- (a) If  $\eta > 1$ , then  $S_1(t) < S_0(t)$  for all t > 0
- (b) If  $\eta < 1$ , then  $S_1(t) > S_0(t)$  for all t > 0
- Thus, any of these three models will NOT allow the possibility of crossing survival functions, i.e.,  $\nexists t_0 > 0$  such that  $S_1(t_0) = S_0(t_0)$

5 ASA BioPharm Section Workshop September 12-14, 2018 NC STATE UNIVERSITY Sujit K. Ghosh Gastric Cancer Data (KM estimates) Cox PH estimates) 1.0 1.0 Chemo Chemo Chemo+Rad Chemo+Rad 0.8 0.8 Survival Probability Survival Probability 0.6 0.6 0.4 0.4 0.2 0.2 0 500 2000 2500 3000 500 2000 1000 1500 0 1000 1500 Time (Days) Time (unique obs Days)


Consider the following simulated scenarios:

- Suppose  $T|Z = z \sim LogNorm(\mu_z, \sigma_z)$  where  $z \in \{0, 1\}$
- $\bullet$  Suppose  $C \sim Exp(\lambda)$  with mean  $1/\lambda$
- $\bullet$  We observe  $Y = \min(T,C)$  for  $z \in \{0,1\}$  and  $\Delta = \mathbb{I}(T \leq C)$
- Observed data:  $\{(Y_i, \Delta_i, Z_i)\}$  for  $i=1,\ldots,n$
- Obtain estimates of the survival functions: S(t|z) for z = 0, 1
  - (i) Using Kaplan-Meier estimates separately for each group
  - (ii) Assuming proportional hazard:  $S(t|z=1)=S(t|z=0)^{\eta}$  for some  $\eta>0$

7

- Consider two scenarios with  $\lambda = 1/400$  and n = 100:
  - Case 1:  $\mu_0 = 3, \sigma_0 = 4, \mu_1 = 3.5, \sigma_1 = 1$
  - Case 2:  $\mu_0 = 2, \sigma_0 = 1, \mu_1 = 5, \sigma_1 = 1$  (AFT with  $\eta = e^{-3}$ )

ASA BioPharm Section Workshop






September 12-14, 2018

Sujit K. Ghosh







 Three of the most popular models: (i) Proportional Hazard (PH) model:  $h(t|z) = h_0(t)\eta(z^{\mathsf{T}}\beta)$  or equivalently  $S(t|z) = S_0(t)^{\eta(z^{\intercal}\beta)}$  for some baseline survival function  $S_0(t)$ (ii) Accelerated Failure Time (AFT) model:  $S(t|z) = S_0(t\eta(z^{\intercal}\beta))$ (iii) Proportional Odds (PO) model:  $\frac{1-S(t|z)}{S(t|z)} = \eta(z^{\mathsf{T}}\beta)\frac{1-S_0(t)}{S_0(t)}$ where  $\eta(\cdot)$  is non-negative increasing function with  $\eta(0) = 1$  (e.g.,  $\eta(u) = e^{u}$ ) • Notice that in the simplest case with  $z \in \{0, 1\}$ : (i) PH:  $S_1(t) = S_0(t)^{\eta}$  (ii) AFT:  $S_1(t) = S_0(t\eta)$  (iii) PO:  $\frac{1-S_1(t)}{S_1(t)} = \eta \frac{1-S_0(t)}{S_0(t)}$ where  $S_1(t) = S(t|z=1)$  and  $S_0(t) = S(t|z=0)$ (a) None of these models allows for crossing survival functions (b) Even when survival functions don't cross but if we fit a PH model to an AFT model we get biased estimates of survival functions • Hence, there is a need to develop more flexible models for S(t|z)ASA BioPharm Section Workshop 11 September 12-14, 2018 THINK A NC STATE UNIVERSITY Sujit K. Ghosh Many extensions are available but often such models are computationally not as efficient as the PH model • The most popular extension is to include a time-varying effect  $\beta(t)$  by replacing  $\beta$ within the PH model Most of the methodologies involving the time-varying effect may turn out to be computationally intensive • Clearly, the appealing feature of easy interpretation and estimation of the PH model comes from the separation of time and covariate effects Once such separation (and hence interpretation and simpler estimation) is lost, why should we insist on (time-varying) PH structure at all? Another important extension in this line of research is referred to as HARE (Hazard Regression), where log of conditional hazard function is modeled as linear splines 12 September 12-14, 2018 ASA BioPharm Section Workshop

NC STATE UNIVERSITY

## Conditional Models for Censored Data

- We consider nonparametric hazard regression based on a sequence of basis functions for right-censored data:  $\{(Y_i, \Delta_i, Z_i); i = 1, \dots, n\}$
- First, we consider the one-sample right-censored data with no covariates
- Following standard practice, assume that  $\tau = \inf\{t : S(t) = 0\} < \infty$
- Notice that likelihood contribution of *i*-th observation  $(Y_i, \Delta_i)$  is  $\Delta_i \log h(Y_i) H(Y_i)$  where  $H(t) = \int_0^t h(s)$  is the cumulative hazard function
- Thus, it is sufficient to model the hazard function h(t)
- For  $m=2,3,\ldots$ , we approximate  $h(\cdot)$  by a sieve of basis functions:

$$h_m(t, \boldsymbol{\gamma}) = \sum_{k=1}^m \gamma_k g_{m,k}(t) = \boldsymbol{\gamma}^{\mathsf{T}} \boldsymbol{g}_m(t), \ 0 \le t < \infty, \tag{1}$$

ASA BioPharm Section Workshop

NC STATE UNIVERSITY

## Sujit K. Ghosh

13

- We use the sequence of Bernstein basis functions:  $g_{m,k}(t) = \frac{m}{\tau} {m-1 \choose k-1} (\frac{t}{\tau})^{k-1} (1 - \frac{t}{\tau})^{m-k} \mathbb{I}(0 \le t \le \tau)$  for  $m = 2, 3, \ldots$  which can be expressed as a density of Beta(k, m - k + 1) at  $t/\tau$
- More specifically, for any continuous hazard function h(t), we can show that

$$\max_{t \in [0,\tau]} |h_m(t, \boldsymbol{\gamma}) - h(t)| \to 0 \text{ as } m \to \infty$$

if we choose  $\gamma_k = h(rac{k-1}{m-1} au)$  for  $k=1,\ldots,m$ 

- Notice that a legitimate hazard function besides being non-negative should also satisfy  $\int_0^\infty h(t)dt = \infty$  (because  $S(\infty) = 0$ )
- Thus, to complete the model specification, we define

$$h_m(t,\gamma) = \sum_{k=1}^m \gamma_k g_{m,k}(t) \mathbb{I}(0 \le t \le \tau) + \frac{m\gamma_m}{\tau} \mathbb{I}(t \ge \tau)$$

THINK AND DO THE EXTRAORDINA

September 12-14, 2018

• Thus, it follows that the log-likelihood function of  $\gamma$  can be written as


$$l(\boldsymbol{\gamma}) = \sum_{i=1}^{n} \{ \Delta_{i} \log(h_{m}(Y_{i}, \boldsymbol{\gamma})) - H_{m}(Y_{i}, \boldsymbol{\gamma}) \}$$
$$= \sum_{i=1}^{n} \{ \Delta_{i} \log(U_{i}^{T} \boldsymbol{\gamma}) - V_{i}^{T} \boldsymbol{\gamma} \},$$
(2)

where  $oldsymbol{\gamma}\in\mathcal{C}_m=[0,\infty)^m$ ,  $U_i=oldsymbol{g}_m(Y_i)$ , and  $V_i=oldsymbol{G}_m(Y_i)$ 

- Notice that the existence and uniqueness of the (sieve) maximum likelihood estimator follows from strict concavity of the log-likelihood function
- Moreover, as the gradient and Hessian of the log-likelihood is available in closed forms, a modified quasi-Newton method can be easily implemented (optim in R)
- It can be shown that the form of log-likelihood of no-covariate case remains essentially the same of that with covariates


ASA BioPharm Section Workshop	15	September 12-14, 2018
NC STATE UNIVERSITY	Sujit K. Ghosh	THRAK AND DD THE EXTRAORDINARY
	Analysis of Gastric Cancer Data	
	ents with locally advanced gastric ment groups (45 patients per grou	
<ul> <li>One group only receive together with the same</li> </ul>	d chemotherapy while the other gro chemotherapy.	oup received radiotherapy
1000 days the patients	n-Meier curves, before the crossing in the group receiving only chemot of combination treatment of chemot ater stage of the study	herapy had better survival

- We estimated the survival functions using the BP model with the order  $m = [n^{0.5}] = 10$
- $\bullet\,$  The results indicate that the estimated smooth curves cross at  $t=952~{\rm days}$



ASA BioPharm Section Workshop








- Generally, patients with higher Karnofsky scores have higher survival rates
- But such association differs across treatment groups and cell types
- Overall, the patients with small cell type in the test treatment group underwent the sharpest decline in survival rates
- While the patients with squamous cell type receiving the test chemotherapy had the best survival profiles among all groups
- Among the patients with small cell type, the patients receiving the standard chemotherapy appear to have better survival rates than those receiving the test chemotherapy
- On the contrary, the patients with squamous cell type, those receiving the test treatment had better survival rates than the ones receiving the standard treatment
- For the patients with adenocarcinoma or large cell type, survival contours are similar across the treatment groups.

ASA BioPharm Section Workshop	21	September 12-14, 2018
NC STATE UNIVERSITY	Sujit K. Ghosh	THINK AND DO THE EXTRAGROINARY
	Concluding Remarks	

- The most remarkable feature of the proposed method is that the log-likelihood, its gradient, and the Hessian matrix all take a relatively simple form
- Additionally, we show that the general simple form of the log-likelihood function holds even in the presence of categorical and continuous covariates
- Under some mild conditions, the proposed sieve maximum likelihood estimator is shown to be consistent and the corresponding rate of convergence is obtained
- The proposed method provides similar or slightly better estimates than the HARE model but the proposed method has computational stability compared to HARE
- Data driven choice of m could deserve more future studies
- Extension of the proposed model to high-dimensional covariates requires careful analysis



• The consistency and the rate of the convergence are obtained using the Hellinger distance as the metric of choice

$$d(\theta_1, \theta_2) = \left\{ \int (\sqrt{p_{\theta_1}} - \sqrt{p_{\theta_2}})^2 d\mu \right\}^{1/2},\tag{3}$$

where  $heta_j= heta_j(\cdot)$  denote hazard functions and  $p_{ heta_j}$ , the induced density (j=1,2)

• Asymptotic properties of  $\hat{h}_m(\cdot)$  are established using the following boundness and smoothness of the true hazard function  $h_0$ :

(I) 
$$\tau = \inf\{t > 0 : \int_0^t h_0(u) du = \infty\} < \infty$$
.  
(II)  $h_0(\cdot)$  is continuous on  $[0, \tau]$  and  $h_0(t) \ge \varepsilon$  for all  $t \in [0, \tau]$  for some  $\varepsilon > 0$   
(III) The first derivative denoted by  $h_0^{(1)}(\cdot)$ , is Holder continuous with the exponent  $\alpha_0$ 

• Hence the parameter space is given by

$$\Theta = \{\theta(\cdot) \in C[0,\tau] : \theta(\cdot) \text{ satisfies (I)-(III)}\}.$$
(4)

• The parameter space  $\Theta$  is approximated by smaller finite dimensional space so called the sieve given by

$$\Theta_m = \left\{ \theta_m(t) = \sum_{k=1}^m \gamma_k g_{m,k}(t) : \boldsymbol{\gamma} = (\gamma_1, \gamma_2, \dots, \gamma_m)^T \in [0, L_{\gamma}]^m \right\}, \quad (5)$$

**Theorem 1.** (Consistency) Suppose the conditions (I)-(II) hold and the sieve  $\Theta_m$  is defined as in (5), then  $\hat{h}_{m,n}(\cdot) \rightarrow_{a.s.} h_0(\cdot)$  as  $m, n \rightarrow \infty$ .

**Theorem 2.** (Rate of Convergence) Suppose the conditions (I)-(III) hold and the sieve  $\Theta_m$  is defined as in (5), if  $m = o(n^{\kappa})$  with  $\kappa = \frac{2}{3+2\alpha_0}$ , then  $d(\hat{h}_{m,n}, h_0) = O_p(n^{-\frac{1+\alpha_0}{3+2\alpha_0}}).$ 

The proofs of these two theorems are given in Osman and Ghosh (2012)

ASA BioPharm Section Workshop

25

September 12-14, 2018